These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients. Duval F; Mokrani MC; Macher JP; Crocq MA; Castro JO; Bailey P; Lataste X Psychopharmacology (Berl); 1993; 110(1-2):177-80. PubMed ID: 7870880 [TBL] [Abstract][Full Text] [Related]
11. Effect of apomorphine on melatonin secretion in normal subjects. Lal S; Isaac I; Pilapil C; Nair NP; Hariharasubramanian N; Guyda H; Quirion R Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(2-3):229-33. PubMed ID: 3628830 [TBL] [Abstract][Full Text] [Related]
12. The effect of methyltestosterone on the growth hormone response to the dopamine receptor agonist, apomorphine. Lal S; Nair NP; Thavundayil JX; Tawar V; Guyda H; Ayotte C Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(2):263-8. PubMed ID: 1871327 [TBL] [Abstract][Full Text] [Related]
13. Drug-induced growth hormone and prolactin responses in schizophrenia research. Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495 [TBL] [Abstract][Full Text] [Related]
14. The effect of Yohimbine, an alpha2 adrenergic receptor antagonist, on the growth hormone response to apomorphine in normal subjects. Lal S; Thavundayil JX; Krishnan B; Nair NP; Schwartz G; Guyda H J Psychiatry Neurosci; 1996 Mar; 21(2):96-100. PubMed ID: 8820174 [TBL] [Abstract][Full Text] [Related]
15. A role for dopamine in growth hormone regulation in the dog. Casanueva F; Betti R; Cocchi D; Zanardi P; Motta T; Müller EE Endocrinology; 1981 Apr; 108(4):1469-75. PubMed ID: 7472276 [TBL] [Abstract][Full Text] [Related]
16. Evidence for endogenous dopaminergic control of GH release in man. Hanew K; Sasaki A; Yoshinaga K Tohoku J Exp Med; 1981 Sep; 135(1):103-8. PubMed ID: 7324044 [TBL] [Abstract][Full Text] [Related]
17. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Meltzer HY; Lee MA; Jayathilake K Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518 [TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man. Lal S; Nair NP; Eugenio H; Thavundayil J; Lizondo E; Wood PL; Etienne P; Guyda H Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):537-44. PubMed ID: 6320299 [TBL] [Abstract][Full Text] [Related]
19. Growth hormone response to a novel growth hormone-releasing tripeptide in horses: interaction with gonadotropin-releasing hormone, thyrotropin-releasing hormone, and sulpiride. Kennedy SR; Thompson DL; Pruett HE; Burns PJ; Deghenghi R J Anim Sci; 2002 Mar; 80(3):744-50. PubMed ID: 11890411 [TBL] [Abstract][Full Text] [Related]
20. Growth hormone response to apomorphine, a dopamine receptor agonist, in normal aging and in dementia of the Alzheimer type. Lal S; Nair NP; Thavundayil JX; Tawar V; Tesfaye Y; Dastoor D; Gauthier S; Guyda H Neurobiol Aging; 1989; 10(3):227-31. PubMed ID: 2664540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]